A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).
Latest Information Update: 08 Jan 2025
Price :
$35 *
At a glance
- Drugs Tarlatamab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms DeLLphi-301
- Sponsors Amgen
- 06 Jan 2025 According to an Amgen media release, announced that the UKs Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorization to IMDYLLTRA for the treatment of adult patients with extensive stage small cell lung cancer based on results from the Phase 2 open label, multicentre study DeLLphi-301.
- 09 Sep 2024 Results (n=100) published in the Amgen Media Release.
- 09 Sep 2024 According to an Amgen media release, the company announced the presentation of long-term results from the Phase 2 DeLLphi-301 study as an oral presentation at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.